Diabetic Peripheral Neuropathy Clinical Trial
Official title:
A Double-blind, Placebo-controlled Randomized Evaluation of the Effect of the Erchonia® FX-635™ on Diabetic Peripheral Neuropathy Pain
Verified date | February 2023 |
Source | Erchonia Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether low level laser therapy is effective in the reduction of foot pain associated with diabetic peripheral neuropathy.
Status | Terminated |
Enrollment | 18 |
Est. completion date | October 5, 2021 |
Est. primary completion date | October 5, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age or older. Significant spontaneous pain of 50 or greater on the 0-100 VAS for the feet overall. - Existing clinical diagnosis of diabetes induced Peripheral Neuropathy. - Significant spontaneous foot pain that occurs comparably bilaterally. - Foot pain is chronic, ongoing for at least 3 months, bilaterally. - Subject has been on a stable anti-diabetic medication regimen or on no anti-diabetic medication regimen for the prior 30 days. - Subject has not used or is willing to abstain from using analgesics within 7 days prior to study start. - Subject has been on a stable dosage of antidepressants for at least 90 days prior to study start and is willing and able to maintain that stable dosage throughout study participation OR subject has not used or is willing to abstain from using antidepressants for 30 days prior to study start. - Subject has been on a stable dosage of any of Neurontin, Lyrica, Tramadol and Opioid medicines such as Ultram and Ultracet for at least 90 days prior to study start and is willing and able to maintain that stable dosage throughout study participation OR subject has not used or is willing to abstain from using any of the these medications for 30 days prior to study start. - Subject has not received or is willing to abstain from receiving any injections of local anesthetics such as lidocaine within 30 days prior to study start. - Subject is able and willing to take over-the-counter Regular Strength Tylenol tablets to manage pain, as needed, throughout the study. - Subject is willing and able to refrain from consuming any over-the-counter and/or prescription medications including muscle relaxants and/or herbal supplements and/or recreational and medical drugs including cannabis intended for the relief of pain and/or inflammation throughout study participation, except for the study-specific pain relief medication of over-the-counter Tylenol. - Subject is willing and able to refrain from engaging in any non-study procedure therapies for the management of foot pain throughout the study, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture. - Can communicate fluently in English and can read and write English sufficiently to comply with the study procedures and complete the information in the Subject Diary. Exclusion Criteria: - Subject's foot pain is undiagnosed, or has been diagnosed as being other than, or in addition to, diabetes induced Peripheral Neuropathy. - Subject's foot pain is unilateral or notably different between the two feet. - Serious organ disease or other serious primary disease merger. - Diabetes ketosis, ketoacidosis or severe infection within the past two weeks. - Current, active chronic pain disease: chronic fatigue syndrome, fibromyalgia, endometriosis, inflammatory bowel disease, interstitial cystitis, peripheral vascular disease. - Cancer or treatment for cancer in the past 6 months. - Surgical intervention to treat diabetic peripheral neuropathy foot pain, including implantation of a pain relief device. - Active infection, wound, or other external trauma to the areas to be treated with the laser. - Medical, physical, or other contraindications for, or sensitivity to, light therapy. - Pregnant, breast feeding, or planning pregnancy prior to the end of study participation. - Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years. - Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements. - Any condition or other variable that in the opinion of the investigator may confound or interfere with the evaluation of the effectiveness of the investigational treatment or otherwise render the subject unable to comply with the requirements of the study protocol. - Involvement in litigation and/or receiving disability benefits related in any way to the parameters of the study. - Participation in a clinical study or other type of research in the past 30 days. |
Country | Name | City | State |
---|---|---|---|
United States | Jeffrey Kleis, DPM | Costa Mesa | California |
United States | Jordan Steinberg, DPM | Florham Park | New Jersey |
United States | Hialeah Hospital Medical Plaza | Hialeah | Florida |
United States | Arizona Institute of Footcare Physicians | Mesa | Arizona |
Lead Sponsor | Collaborator |
---|---|
Erchonia Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Participants With a 30% or Greater Change in Visual Analog Scale (VAS) Pain Scores | The Visual Analog Scale (VAS) assesses level or degree of pain. It is a horizontal line anchored on the left by the label '0: no pain at all' and on the right by the label '100: worst pain imaginable'. The subject marks a location on the 0-100 line that appears to represent any level of pain he or she is experiencing at that time. This marking is measured with a 0 to 100 mm ruler and the number recorded. For the primary study outcome, the percent change in the VAS pain score recorded at baseline and endpoint is calculated for each subject. Individual subject success is a 30% or greater change in VAS pain scores. A negative (-) percent change indicates a decrease in pain level and is positive for individual subject success. A positive (+) percent change indicates an increase in pain level and is negative for individual subject success. Overall study success is defined as a 35% or greater difference between the proportion of individual successes in each treatment group. | Baseline and 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04638556 -
Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
|
||
Completed |
NCT05580705 -
Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy
|
N/A | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT00835757 -
Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT00553592 -
Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
|
Phase 2 | |
Recruiting |
NCT05863793 -
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT05041816 -
Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT06074562 -
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Recruiting |
NCT04457531 -
LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy
|
Early Phase 1 | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02056431 -
Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01681290 -
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01474772 -
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
|
Phase 3 | |
Completed |
NCT01086150 -
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03447756 -
Titration Study of ABX-1431
|
Phase 1 | |
Completed |
NCT04688671 -
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
|
Phase 2 | |
Completed |
NCT04984044 -
Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms
|
N/A | |
Completed |
NCT06130917 -
Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN.
|
N/A | |
Completed |
NCT01496365 -
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 |